Results 61 to 70 of about 1,213 (150)
FEBS Open Bio, 2019 The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested ...
Ryo Goto +14 more
doaj +1 more source
Journal of Diabetes Investigation, 2020 Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood.
Mayu Tochiya +11 more
doaj +1 more source
Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes
Food Science &Nutrition, Volume 14, Issue 3, March 2026.Boscisucrophage (BSP) significantly reduced blood glucose and HbA1c, increased urine glucose excretion, and improved functional symptoms in T2DM patients resistant to oral antihyperglycemic drugs. BSP showed no adverse effects on liver or kidney function.
Bruno Eto +11 more
wiley +1 more source
Long‐term remission in gout: Challenges and future opportunities
Rheumatology &Autoimmunity, Volume 6, Issue 1, Page 7-15, March 2026.Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley +1 more source
Nephrology, Volume 31, Issue 2, February 2026.This study analysed urinary volatile organic compounds (VOCs) to identify non‐invasive biomarkers for monitoring metabolic mechanisms of SGLT2 inhibitor renoprotection in diabetic kidney disease. The results revealed significantly higher levels of urinary acetone and 2‐pentanone in the treated group, indicating that these ketone‐related VOCs serve as ...
Risa Hara +6 more
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.ABSTRACT Purpose Diabetic ketoacidosis (DKA) is an important identified risk of treatment with the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin, particularly in patients with type 1 diabetes mellitus (T1DM). We evaluated the DKA incidence rate (IR) among dapagliflozin‐treated Japanese patients with T1DM receiving concomitant insulin.
Reiko Tamura +6 more
wiley +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 1, Page 25-33, January 2026.ABSTRACT Aims/Introduction This study aimed to investigate whether the use of sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) is associated with an increase in hemoglobin in the presence of chronic inflammation. Materials and Methods This is a matched‐pair cohort study.
Miho Murashima +9 more
wiley +1 more source
Journal of Diabetes Research, Volume 2026, Issue 1, 2026.Background Solid organ transplant recipients with diabetes mellitus face unique challenges in glycemic control, compounded by the metabolic effects of immunosuppressants. Although sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective in diabetes, evidence for their use in transplant recipients remains limited.
Min Jung Geum +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue 12, Page 6999-7009, December 2025.Abstract Aim Sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) offer significant cardiorenal benefits for people with type 2 diabetes (PwT2D). However, concerns remain regarding their association with diabetes‐related ketoacidosis (DKA). (1) To compare demographics, precipitating factors, biochemical features, management, and outcomes of acute DKA ...
Angelica Sharma +11 more
wiley +1 more source